MedGenome discussed proprietary cancer immunotherapeutic platform

Press

MedGenome to discuss its proprietary cancer immunotherapeutics platform

OncoPept is an integrated platform that interrogates tumor and its microenvironment to discover potential cancer vaccine candidates as therapeutics and biomarkers of response.

MedGenome-to-discuss-its-proprietary-cancer-Dail-News

MedGenome-to-discuss-its-proprietary-cancer-i-Boston.com_

MedGenome-to-discuss-its-proprietary-cancer-International-Business

MedGenome-to-discuss-its-proprietary-cancer-Pharmaceutical-Industry-Today

MedGenome-to-discuss-its-proprietary-cancer-Science-News-Today

MedGenome-to-discuss-its-proprietary-cancer-SiliconValley.com_

MedGenome-to-discuss-its-proprietary-cancer-wallstreetselect.com_

http://markets.financialcontent.com/mnglang.dailynews/news/read/31544116/MedGenome_to_discuss_its_proprietary_cancer_immunotherapeutics_platform_at_the_San_Diego_conference

http://pharmaceuticals.einnews.com/pr_news/311754438/medgenome-to-discuss-its-proprietary-cancer-immunotherapeutics-platform-at-the-san-diego-conference

http://science.einnews.com/pr_news/311754438/medgenome-to-discuss-its-proprietary-cancer-immunotherapeutics-platform-at-the-san-diego-conference

http://markets.financialcontent.com/mng- ba.siliconvalley/news/read/31544116/MedGenome_to_discuss_its_proprietary_cancer_immunotherapeutics_platform_at_the_San_Diego_conference

https://www.boston.com/tag/finance

http://investor.wallstreetselect.com/wss/news/read?GUID=31544116

http://markets.financialcontent.com/ibtimes/news/read?GUID=315441166

Considering Genomic Research?

Company

Resources

Research

Diagnostics

India

Contact